StockNews.com Initiates Coverage on Ayala Pharmaceuticals (NASDAQ:ADXS)

Stock analysts at StockNews.com initiated coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a report issued on Wednesday. The firm set a “sell” rating on the stock.

Ayala Pharmaceuticals Price Performance

Shares of ADXS stock opened at $0.11 on Wednesday. The company has a market cap of $4.48 million, a P/E ratio of -0.01 and a beta of 1.70. Ayala Pharmaceuticals has a twelve month low of $0.00 and a twelve month high of $1.49. The business has a fifty day simple moving average of $0.05 and a 200 day simple moving average of $0.10.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.